Non-human animal having a functionally disrupted SLP-76 gene
US6194633A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 26, 1998 |
| Grant date | Feb 27, 2001 |
| Priority date | — |
| Expiry date | Jan 26, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A nonhuman animal having somatic and germ cells in which at least one allele of an endogenous SLP-76 gene is functionally disrupted is provided. The animal may be heterozygous or, more preferably, homozygous for the SLP-76 gene disruption and is preferably a mouse. In homozygous animals, the percentage of peripheral T cells is substantially decreased compared to wildtype animals, whereas the percentage of B cells and macrophages in the periphery is substantially normal, indicating that SLP-76 disruption causes a profound block in T cell development. The animals of the invention can be used, for example, as controls to evaluate the efficacy of SLP-76 inhibitors and to identify disease conditions that can be treated with SLP-76 inhibitors. A transgenic nonhuman animal having a functionally disrupted endogenous SLP-76 gene but which has been reconstituted with an exogenous SLP-76 transgene (e.g., a human SLP-76 gene or a SLP-76 gene whose expression in targeted to a particular cell population) is also provided. An animal that has been reconstituted with a human SLP-76 gene can be used to identify agents that modulate human SLP-76 in vivo. Nucleic acid constructs for functionally disru…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.